Genmab A/S (NASDAQ:GMAB) Sets New 12-Month High - Should You Buy?

Key Points

• Genmab shares reached a new 52-week high of $35.70 and were recently trading around $35.36, with the stock up about 0.1% and above its 50- and 200-day moving averages.
• Analyst sentiment is favorable, with a consensus “Moderate Buy” rating and a $39.50 target price; several firms recently raised targets to $42–$43 or upgraded the stock to Buy.
• Genmab exceeded quarterly expectations, reporting $0.54 in EPS versus $0.37 expected and $1.16 billion in revenue versus $1.12 billion forecast. The biotechnology company develops antibody-based medicines, including DARZALEX, Kesimpta and Tivdak.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday. The company traded as high as $35.70 and last traded at $35.36, with a volume of 2794569 shares traded. The stock had previously closed at $35.32.

Analyst Ratings Changes

A number of research firms have issued reports on GMAB. Guggenheim increased their target price on Genmab A/S from $40.00 to $42.00 and gave the stock a "buy" rating in a report on Friday, August 7th. TD Cowen upgraded Genmab A/S from a "hold" rating to a "buy" rating and boosted their price target for the company from $32.00 to $43.00 in a report on Wednesday, July 22nd. New Street Research set a $43.00 price objective on Genmab A/S in a research report on Wednesday, July 22nd. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Genmab A/S in a report on Monday, September 14th. Finally, Weiss Ratings upgraded Genmab A/S from a "hold (c)" rating to a "hold (c+)" rating in a report on Tuesday, September 1st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $39.50.

Genmab A/S Trading Up 0.1%

The firm has a market capitalization of $22.07 billion, a P/E ratio of 27.84, a PEG ratio of 1.92 and a beta of 0.84. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The firm has a 50 day moving average of $32.26 and a 200-day moving average of $28.74.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.54 EPS for the quarter, beating analysts' consensus estimates of $0.37 by $0.17. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. On average, equities research analysts predict that Genmab A/S Sponsored ADR will post 1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC acquired a new stake in shares of Genmab A/S during the 2nd quarter valued at $31,000. V Square Quantitative Management LLC acquired a new stake in shares of Genmab A/S during the first quarter valued at about $34,000. MidFirst Bank bought a new stake in shares of Genmab A/S during the fourth quarter worth about $56,000. Nykredit A S bought a new stake in shares of Genmab A/S during the second quarter worth about $58,000. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Genmab A/S by 39.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 3,032 shares of the company's stock valued at $93,000 after buying an additional 854 shares during the period. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering, developing and commercializing differentiated antibody-based medicines. The company's research platforms include technologies designed to create human antibodies and bispecific antibodies that engage the immune system to target cancer and other serious diseases.

Genmab's products and partnered medicines include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; Kesimpta (ofatumumab) for multiple sclerosis, developed with Novartis; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Pfizer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.